108 results
8-K
EX-99.2
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
Reich
1 van Baarsen LG, et al. Arthritis Res Ther. 2014; 16:426 - 436; 2 Schett G, et al. Nature Reviews Rheumatology. 2017; 13:731 - 741; 3 Prinz JC … and McInnes IB, Nature Medicine. 2012; 18:1018 - 1019; 7 Reich K. J Eur Acad Dermatol Venereol. 2009; 23 Suppl 1:15 - 21; Clinical pictures K. Reich
8-K
EX-99.2
5qq2 t2jan1iq
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-1.1
ca75c p6p
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-5.1
qtq25i5m
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
424B5
f2l1ii4 ns
29 Jun 23
Prospectus supplement for primary offering
4:02pm
424B5
ezdzer2
26 Jun 23
Prospectus supplement for primary offering
4:23pm